Differential anti-inflammatory activity of HDAC inhibitors in human macrophages and rat arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 356, Issue 2, 2016, Pages 387-396

  Lohman, Rink Jan ^a   Iyer, Abishek ^a   Fairlie, Thomas J ^a   Cotterell, Adam ^a   Gupta, Praveer ^a   Reid, Robert C ^a   Vesey, David A ^a   Sweet, Matthew J ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TERT BUTYL[4 [3 [[7 (HYDROXYAMINO) 7 OXOHEPTYL]CARBAMOYL]ISOXAZOL 5 YL]PHENYL]CARBAMATE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VORINOSTAT; AUTACOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLLAGEN-INDUCED ARTHRITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; CELL SURVIVAL; COCULTURE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CELL SURVIVAL; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGES; RATS; RATS, WISTAR;

EID: 84959431745     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.229328     Document Type: Article

References (60)

1. Alias E, Dharmapatni AS, Holding AC, Atkins GJ, Findlay DM, Howie DW, Crotti TN, and Haynes DR (2012) Polyethylene particles stimulate expression of ITAMrelated molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomater 8: 3104-3112.
2. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, and van den Berg WB (2000) Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 43: 1951-1959.
3. Bode KA and Dalpke AH (2011) HDAC inhibitors block innate immunity. Blood 117: 1102-1103.
4. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, and Dalpke AH (2007) Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122: 596-606.
5. Cantley MD, Fairlie DP, Bartold PM, Marino V, Gupta PK, and Haynes DR (2015) Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis. Rheumatology (Oxford) 54: 1713-1723.
6. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, and Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
7. Chung YL, Lee MY, Wang AJ, and Yao LF (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8: 707-717.
8. Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, Poupot R, and Cantagrel A (2013) Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52: 590-598.
9. Dekker FJ, van den Bosch T, and Martin NI (2014) Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. Drug Discov Today 19: 654-660.
10. Dinarello CA, Fossati G, and Mascagni P (2011) Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 17: 333-352.
11. Fairlie DP and Sweet MJ (2012) HDACs and their inhibitors in immunology: Teaching anticancer drugs new tricks. Immunol Cell Biol 90: 3-5.
12. Falkenberg KJ and Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13: 673-691.
13. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, and Dinarello CA (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 17: 353-362.
14. Grabiec AM and Reedquist KA (2013) The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 9: 311-318.
15. Grabiec AM, Tak PP, and Reedquist KA (2008) Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HATs on? Arthritis Res Ther 10: 226-238.
16. Gupta P, Reid RC, Iyer A, Sweet MJ, and Fairlie DP (2012) Towards isozymeselective HDAC inhibitors for interrogating disease. Curr Top Med Chem 12: 1479-1499.
17. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, and Hume DA, et al. (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 87: 1103-1114.
18. Halili MA, Andrews MR, Sweet MJ, and Fairlie DP (2009) Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 9: 309-319.
19. Hildebrand D, Bode KA, Rieß D, Cerny D, Waldhuber A, Römmler F, Strack J, Korten S, Orth JH, and Miethke T, et al. (2014) Granzyme A produces bioactive IL- 1b through a nonapoptotic inflammasome-independent pathway. Cell Reports 9: 910-917.
20. Hohenhaus DM, Schaale K, Le Cao KA, Seow V, Iyer A, Fairlie DP, and Sweet MJ (2013) An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation. Immunobiology 218: 1345-1353.
21. Hsieh IN, Liou JP, Lee HY, Lai MJ, Li YH, and Yang CR (2014) Preclinical antiarthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis 5: E1166.
22. Iyer A, Fairlie DP, and Brown L (2012) Lysine acetylation in obesity, diabetes and metabolic disease. Immunol Cell Biol 90: 39-46.
23. Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, Fairlie DP, and Brown L (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 159: 1408-1417.
24. Joosten LA, Leoni F, Meghji S, and Mascagni P (2011) Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med 17: 391-396.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, and Altman DG; NC3Rs Reporting Guidelines Working Group (2010) Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, and Kim N (2009) The mechanism of osteoclast differentiation induced by IL-1. J Immunol 183: 1862-1870.
27. Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, and Burmester GR (2000) Macrophages in rheumatoid arthritis. Arthritis Res 2: 189-202.
28. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, and Billadeau DD (2008) Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 51: 4370-4373.
29. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, and Adema GJ (2014) HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 5: 6558-6572.
30. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, and Reznikov LL, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11: 1-15.
31. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Donà G, Fossati G, Sozzani S, and Azam T, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99: 2995-3000.
32. Li J, Hsu HC, and Mountz JD (2012) Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep 14: 445-454.
33. Li M, Liu X, Sun X, Wang Z, Guo W, Hu F, Yao H, Cao X, Jin J, and Wang PG, et al. (2013) Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes. Inflammation 36: 888-896.
34. Liddiard K and Taylor PR (2015) Understanding local macrophage phenotypes in disease: Shape-shifting macrophages. Nat Med 21: 119-120.
35. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, and Clément-Lacroix P (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862-872.
36. Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, and Fairlie DP (2012) An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J 26: 2877-2887.
37. McGee-Lawrence ME and Westendorf JJ (2011) Histone deacetylases in skeletal development and bone mass maintenance. Gene 474: 1-11.
38. Moss ML, Sklair-Tavron L, and Nudelman R (2008) Drug insight: Tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4: 300-309.
39. Murray PJ and Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723-737.
40. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N, Yoshida A, Hirohata S, Ohtsuka A, and Ozaki T (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16: 723-732.
41. Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, and Joosten LA (2015) Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol 33: 49-77.
42. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, and Miconnet I, et al. (2011) Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117: 1205-1217.
43. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW, and Greene MI (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 87: 99-104.
44. Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman KA, Labzin LI, Semple CA, Kapetanovic R, and Fairbairn L, et al. (2012) Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci USA 109: E944-E953.
45. Schroder K and Tschopp J (2010) The inflammasomes. Cell 140: 821-832.
46. Schroeder TM and Westendorf JJ (2005) Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 20: 2254-2263.
47. Seow V, Lim J, Iyer A, Suen JY, Ariffin JK, Hohenhaus DM, Sweet MJ, and Fairlie DP (2013) Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a. J Immunol 191: 4308-4316.
48. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, and Sweet MJ (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32: 335-343.
49. Soler Palacios B, Estrada-Capetillo L, Izquierdo E, Criado G, Nieto C, Municio C, González-Alvaro I, Sánchez-Mateos P, Pablos JL, and Corbí AL, et al. (2015) Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J Pathol 235: 515-526.
50. Stowell JC, Huot RI, and Van Voast L (1995) The synthesis of N-hydroxy-N'- phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. J Med Chem 38: 1411-1413.
51. Subramanian S, Bates SE, Wright JJ, Espinoza-Degado I, and Piekarz RL (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3: 2751-2767.
52. Sweet MJ, Shakespear MR, Kamal NA, and Fairlie DP (2012) HDAC inhibitors: Modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 90: 14-22.
53. Taylor PC and Williams RO (2015) Combination cytokine blockade: The way forward in therapy for rheumatoid arthritis? Arthritis Rheumatol 67: 14-16.
54. Vignery A (2005) Macrophage fusion: The making of osteoclasts and giant cells. J Exp Med 202: 337-340.
55. Vojinovic J and Damjanov N (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 17: 397-403.
56. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, and Seto E, et al. (2011) Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 186: 3986-3996.
57. Wei S, Kitaura H, Zhou P, Ross FP, and Teitelbaum SL (2005) IL-1 mediates TNFinduced osteoclastogenesis. J Clin Invest 115: 282-290.
58. West AC and Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124: 30-39.
59. West AC, Smyth MJ, and Johnstone RW (2014) The anticancer effects of HDAC inhibitors require the immune system. OncoImmunology 3: E27414.
60. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, and Miyamoto K, et al. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202: 345-351.